Tech Company Financing Transactions
Kezar Life Sciences Funding Round
Kezar Life Sciences closed a $23 million Series A funding round on 6/18/2015. Investors included AJU IB Investment, Cormorant Asset Management and EcoR1 Capital Management.
Transaction Overview
Company Name
Announced On
6/18/2015
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Proceeds Purpose
The capital raised in the Series A will be used to advance Kezar's lead immunoproteasome inhibitor candidate into Phase 1a and 1b clinical trials, with the goal of demonstrating safety and efficacy in patients with autoimmune disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4000 Shoreline Ct. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Kezar Life Sciences, a privately held company based in South San Francisco, was founded in 2015 to develop drugs to revolutionize the treatment of autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Fowler
Co-Founder
Jack Taunton
President
Christopher Kirk
Browse more venture capital transactions:
Prev: 6/18/2015: Managed by Q venture capital transaction
Next: 6/18/2015: Cure Forward venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs